MK0518 (raltegravir)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIV InfectionHIV InfectionsHIV-1 Infection

Phase 1

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

CompletedNCT01000818

Merck Sharp & Dohme LLCHIV-1 Infection, HIV Infections

Start: 2008-06-30End: 2009-03-31Updated: 2017-03-21

Phase 3

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

TerminatedNCT00443703

Merck Sharp & Dohme LLCHIV Infection

Start: 2007-05-31End: 2009-04-30Updated: 2017-03-21

Related Papers

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

2010-01-12214 citations